The global prevalence of diabetes mellitus (DM) has led to widespread multi-system
damage, especially in cardiovascular and renal functions, heightening morbidity and …

Mammals maintain thermoregulation in the face of cold environmental temperatures by
activating bioenergetic mechanisms that increase heat production. Included in this response …

The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of
type 2 diabetes and obesity holds great promise for improving glycaemic control and weight …

Objective Glucagon-like peptide 1 (GLP-1) receptor agonists reduce food intake, producing
remarkable weight loss in overweight and obese individuals. While much of this weight loss …

G protein-coupled receptors (GPCRs) are important, potential drug targets for the treatment
of metabolic disorders, such as obesity. GPCRs crosstalk with several transducers, including …

Tirzepatide is a dual GIP and GLP-1 receptor co-agonist which is approved for glucose-
lowering therapy in type 2 diabetes. Here, we explored its effects on beta cell function …

Abstract Glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic
polypeptide receptor (GIPR) are transmembrane receptors involved in insulin, glucagon and …

Investigations conducted since 2018 have identified several host-defense peptides present
in frog skin secretions whose properties suggest the possibility of their development into a …

Under chronic stress, cells must balance competing demands between cellular survival and
tissue function. In metabolic dysfunction-associated steatotic liver disease (MASLD, formerly …

Abstract Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United
States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes …